| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥39.8B | ¥31.1B | +28.1% |
| Operating Income | ¥4.8B | ¥-2.1B | +114.1% |
| Ordinary Income | ¥4.4B | ¥-3.6B | +236.3% |
| Net Income | ¥5.0B | ¥0.6B | +787.5% |
| ROE | 7.2% | 1.0% | - |
FY2025 consolidated results for RaQualia Pharma showed a significant recovery. Revenue reached 39.8 billion yen (YoY +28.1%), operating income improved to 4.8 billion yen from negative 2.1 billion yen in the prior year (YoY +114.1%), representing a return to profitability. Ordinary income was 4.4 billion yen versus negative 3.6 billion yen prior year (YoY +236.3%), and net income attributable to owners increased to 5.0 billion yen from 0.6 billion yen (YoY +787.5%). The company achieved black ink across all profit lines after prior year losses. Operating margin reached 12.2%, up from negative 6.8% in the prior year, marking a substantial improvement of 19.0 percentage points. However, operating cash flow deteriorated to negative 3.5 billion yen from positive 1.8 billion yen (YoY -296.7%), indicating a disconnect between reported profits and cash generation. Free cash flow was negative 2.3 billion yen. This marks a turning point from loss to profit on the income statement, though cash flow quality warrants close monitoring.
Revenue grew 28.1% to 39.8 billion yen, driven by the single pharmaceutical R&D business segment. The company operates exclusively in drug discovery and development without segment diversification. Revenue growth was accompanied by improved cost management, enabling operating income to swing from negative 2.1 billion yen to positive 4.8 billion yen. The operating profit turnaround of 6.9 billion yen represents a dramatic improvement in operational efficiency. Non-operating items showed a net negative impact of 0.5 billion yen, comprising non-operating income of 0.7 billion yen offset by non-operating expenses of 1.2 billion yen. Non-operating income included interest income of 0.2 billion yen, dividend income of 0.1 billion yen, and foreign exchange gains of 0.4 billion yen. Non-operating expenses consisted primarily of interest expenses of 0.6 billion yen and foreign exchange losses of 0.4 billion yen, indicating volatility in FX exposure. The gap between ordinary income of 4.4 billion yen and net income of 5.0 billion yen (difference of 0.6 billion yen, or 13.6%) was driven by non-recurring factors. Extraordinary income included gains on sale of securities of 0.1 billion yen, while extraordinary losses were 0.1 billion yen, resulting in minimal net impact. Income tax expense of 1.6 billion yen against profit before tax of 4.4 billion yen yielded an effective tax rate of 37.7%. The difference between net income reported (2.7 billion yen attributable to owners) and headline net income (5.0 billion yen) requires clarification, but comprehensive income of 2.6 billion yen aligns more closely with the attributable figure. The company exhibited the revenue up/profit up pattern, with both top line and bottom line showing strong improvement. However, this improvement included contributions from FX gains and securities sales that may not recur. The company's full-year forecast is notably conservative, projecting operating income of only 1.6 billion yen (YoY -65.9%) and negative EPS, suggesting management views current period results as containing non-repeatable positive factors.
[Profitability] ROE was 7.2%, improved from negative territory in the prior year as the company returned to profitability. Operating margin reached 12.2%, up 19.0 percentage points from negative 6.8% YoY, reflecting significant operational efficiency gains. EBITDA margin was 17.2%, with EBITDA of 6.9 billion yen providing a view of cash-based earnings power. Basic EPS improved to 11.53 yen from negative 22.87 yen YoY, a swing of 34.40 yen per share. Diluted EPS was 11.36 yen. However, profitability sustainability is questionable given the conservative full-year forecast projecting negative EPS of negative 2.58 yen and the contribution of non-recurring items such as FX gains and securities sales. [Cash Quality] Cash and deposits stood at 32.4 billion yen, providing strong liquidity coverage of short-term obligations. The current ratio was 445.7%, indicating robust short-term debt coverage of 4.5 times. However, operating cash flow was negative 3.5 billion yen despite positive net income of 2.7 billion yen, yielding an OCF to net income ratio of negative 1.30 times, which signals poor earnings quality and cash conversion. Days sales outstanding deteriorated sharply to approximately 177 days as trade receivables surged 179.8% to 19.3 billion yen, creating a significant working capital drain. The cash conversion cycle has lengthened considerably, with receivables growth far outpacing revenue growth, raising concerns about collection practices or contract terms. [Investment Efficiency] Total asset turnover was 0.38 times, reflecting the asset-heavy nature of the pharmaceutical development business. Capital expenditure was 0.7 billion yen, representing only 0.33 times depreciation and amortization of 2.0 billion yen, suggesting potential underinvestment in fixed assets. Intangible assets totaled 37.3 billion yen, including goodwill of 37.0 billion yen, representing 35.5% of total assets. The goodwill to net equity ratio was 53.7%, indicating substantial impairment risk if business performance deteriorates. [Financial Health] Equity ratio was 65.6%, up from 57.7% in the prior year, reflecting improved capitalization from retained earnings accumulation. Total equity increased to 69.0 billion yen from 55.7 billion yen. Interest-bearing debt was 21.4 billion yen in long-term loans, with a debt-to-equity ratio of 0.31 times, representing conservative leverage. The debt-to-EBITDA ratio was 3.12 times, which is elevated but manageable. Interest coverage ratio was 8.18 times based on operating income plus interest and dividends received versus interest paid, providing adequate cushion for debt service. BPS improved to 280.00 yen from prior period levels as equity strengthened.
Operating cash flow was negative 3.5 billion yen, deteriorating from positive 1.8 billion yen in the prior year, representing a swing of negative 5.3 billion yen. This negative operating CF occurred despite net income of 2.7 billion yen attributable to owners, indicating poor cash conversion with an OCF to net income ratio of negative 1.30 times. Operating cash flow before working capital changes was negative 1.9 billion yen, and working capital movements absorbed an additional 1.6 billion yen. The primary driver of the cash drain was a 12.4 billion yen increase in trade receivables, which swamped the modest 0.1 billion yen increase in trade payables and 0.1 billion yen decrease in inventories. Contract liabilities decreased by 0.4 billion yen, providing another headwind to operating cash generation. Income taxes paid amounted to 1.4 billion yen. Interest and dividends received contributed 0.3 billion yen while interest paid was 0.6 billion yen, resulting in net financial cash outflow of 0.3 billion yen. Investing cash flow was positive 1.2 billion yen, driven by inflows that exceeded capital expenditure of 0.7 billion yen, likely from disposal of investment securities or other financial assets given the reported gain on sale of securities. Financing cash flow was positive 3.8 billion yen, providing liquidity to offset operating and investing cash needs, though the composition of this inflow requires further analysis of debt drawdowns or equity financing. Free cash flow, calculated as operating CF plus investing CF, was negative 2.3 billion yen, indicating the company consumed cash from core operations and investments combined. The negative FCF of 2.3 billion yen against EBITDA of 6.9 billion yen yields an FCF to EBITDA ratio of negative 0.33 times, confirming weak cash generation relative to earnings. Cash and deposits remained substantial at 32.4 billion yen, providing a liquidity buffer, though the ongoing cash consumption pattern is unsustainable without improvement in working capital management.
Ordinary income of 4.4 billion yen versus operating income of 4.8 billion yen shows a net non-operating expense of approximately 0.4 billion yen. Non-operating income totaled 0.7 billion yen, comprising interest income of 0.2 billion yen, dividend income of 0.1 billion yen, and foreign exchange gains of 0.4 billion yen as primary components. Non-operating expenses were 1.2 billion yen, consisting of interest expense of 0.6 billion yen and foreign exchange losses of 0.4 billion yen. The FX impact netted to approximately zero (gains 0.4 billion yen, losses 0.4 billion yen), suggesting currency exposure that may create volatility but had minimal net effect in the current period. Extraordinary items contributed a modest net positive, with gains on sale of investment securities of 0.1 billion yen offsetting extraordinary losses of 0.1 billion yen. Non-operating and extraordinary items combined represented approximately 1.3% of revenue, indicating limited distortion from one-time factors, though the FX gains and securities sales are inherently non-recurring. The divergence between operating cash flow and net income is the most significant earnings quality concern. Operating CF of negative 3.5 billion yen versus net income of 2.7 billion yen (or 5.0 billion yen depending on classification) indicates that reported profits are not translating to cash, primarily due to the 12.4 billion yen increase in receivables. This working capital build absorbs more than the total reported income, suggesting either aggressive revenue recognition ahead of cash collection, extended payment terms with customers, or collection difficulties. The accruals component is strongly negative, indicating earnings are supported by non-cash accruals rather than cash realization. Depreciation and amortization of 2.0 billion yen provided a non-cash add-back, but this was insufficient to offset the working capital drain. Overall, earnings quality is weak due to poor cash conversion, heavy reliance on receivables growth, and underinvestment relative to depreciation. The presence of FX gains and securities sales, while small, adds an element of non-recurring support to reported results.
Full-year revenue guidance is 39.8 billion yen, which equals the actual reported result, indicating the fiscal year has concluded and this is final reported performance rather than interim progress. Operating income forecast is 1.6 billion yen (YoY -65.9%) compared to actual 4.8 billion yen, and ordinary income forecast is 0.9 billion yen (YoY -80.4%) compared to actual 4.4 billion yen. EPS forecast is negative 2.58 yen versus actual basic EPS of 11.53 yen. This represents a significant downward revision or reflects management's expectation that the strong current period results will not continue into the next fiscal year. The forecast assumptions noted in the disclosure indicate that projections are based on currently available information and reasonable assumptions, with explicit disclaimer that actual results may differ materially. The dramatic gap between current period results and forward guidance suggests that current period performance benefited from non-recurring factors such as the FX gains, securities sales, or one-time revenue recognition that management does not expect to repeat. The lack of interim progress metrics (Q1, Q2, Q3 benchmarks) confirms this is full-year reporting. Given the full-year forecast shows significant profit decline from current results, investors should interpret current period strength as potentially transitory. The conservative forecast aligns with the weak cash flow generation and elevated receivables, suggesting management has concerns about revenue sustainability or collection. No order backlog data is available to assess forward revenue visibility.
The company paid no dividends for the full year, maintaining its no-dividend policy. Both interim and year-end dividends were zero yen per share. Given the dividend is zero, the payout ratio cannot be calculated. The company has no established dividend policy based on the current period results, and retained earnings remain modest at 2.3 billion yen despite the return to profitability. Share repurchases were minimal at 0.0 billion yen (effectively zero), indicating no capital return to shareholders through buybacks. Total shareholder return ratio combining dividends and buybacks is therefore zero percent. The absence of dividends is consistent with the negative free cash flow of 2.3 billion yen and negative operating cash flow of 3.5 billion yen, as the company lacks cash generation capacity to support distributions. Even with cash and deposits of 32.4 billion yen on the balance sheet, the ongoing cash consumption pattern and working capital challenges make dividend initiation unlikely in the near term. The forward guidance projecting negative EPS of negative 2.58 yen further supports the expectation that no dividend will be paid in the coming fiscal year. Investors seeking income should note that capital returns are not part of the company's current strategy, with all available capital retained to fund operations and manage working capital needs.
Clinical development and regulatory approval risk represents the primary uncertainty facing this pharmaceutical R&D business. As a single-segment drug discovery company, pipeline success or failure directly determines revenue generation, with binary outcomes from clinical trials and approval processes creating high earnings volatility. The company's operating results swung from negative 2.1 billion yen to positive 4.8 billion yen between periods, illustrating the magnitude of potential fluctuations. Working capital and cash collection risk is quantifiably elevated, with trade receivables increasing 179.8% to 19.3 billion yen, driving days sales outstanding to approximately 177 days, well above typical norms. This deterioration caused operating cash flow to turn negative 3.5 billion yen despite positive net income, indicating either aggressive revenue recognition practices, extended payment terms that strain liquidity, or collection difficulties with counterparties. If receivables prove uncollectible or payment terms extend further, the company's cash position of 32.4 billion yen could erode rapidly despite current strength. Goodwill and intangible asset impairment risk is substantial, with goodwill of 37.0 billion yen representing 53.7% of net equity and total intangible assets of 37.3 billion yen comprising 35.5% of total assets. Any business underperformance, failed clinical trials, or reduced valuation of acquired assets could trigger material impairment charges. The company's conservative forward guidance projecting sharp profit decline and negative EPS suggests management recognizes near-term performance headwinds that could pressure asset valuations. Given debt-to-EBITDA of 3.12 times, an impairment that reduces EBITDA could quickly elevate leverage ratios and debt service concerns.
[Industry Position] (Reference - Proprietary Analysis) RaQualia Pharma operates in the pharmaceutical R&D sector as a single-segment drug discovery business. The company's FY2025 operating margin of 12.1% represents a significant improvement from prior year losses and approaches mid-tier pharmaceutical industry standards. Revenue growth of 28.1% substantially exceeds typical pharmaceutical industry organic growth rates, though the sustainability of this expansion is questioned by management's own conservative forward guidance projecting profit declines. The company's ROE of 7.2% reflects recent return to profitability but remains below typical pharmaceutical industry medians in the 10-15% range for established players. Financial health metrics show relative strength, with an equity ratio of 65.6% providing conservative capitalization compared to industry peers. The debt-to-equity ratio of 0.31 times indicates lower leverage than many pharmaceutical companies that operate with D/E ratios of 0.5 to 1.0 times. However, cash flow generation presents a significant weakness relative to industry norms. The pharmaceutical sector typically demonstrates strong cash conversion with operating CF to net income ratios above 1.0 times, whereas RaQualia's negative 1.30 times ratio indicates poor earnings quality. The company's days sales outstanding of approximately 177 days significantly exceeds pharmaceutical industry medians of 60-90 days, suggesting either unusual contract structures or collection challenges. Intangible asset intensity is high even by pharmaceutical industry standards, with intangibles comprising 35.5% of total assets and goodwill representing 53.7% of equity. While drug development companies inherently carry substantial intangible assets from licensing and M&A, this concentration creates above-average impairment risk. The company's liquidity position with 32.4 billion yen in cash and a current ratio of 445.7% exceeds industry norms, providing a safety buffer that partially offsets weak operating cash flow. Overall positioning shows strong balance sheet liquidity and conservative leverage, but operational cash generation and working capital management require substantial improvement to meet pharmaceutical sector benchmarks. The disconnect between reported profitability and cash generation, combined with elevated receivables and conservative forward guidance, distinguishes this company's risk profile from more established pharmaceutical peers with proven cash-generative business models.
Operational turnaround with profitability questions: The company achieved a dramatic swing from operating loss of 2.1 billion yen to operating profit of 4.8 billion yen, with revenue growth of 28.1% driving the improvement. However, management's own forward guidance projects sharp profit decline with negative EPS expected, suggesting the current period benefited from non-recurring factors or revenue timing that will not persist. This creates uncertainty about whether the operational turnaround represents sustainable improvement or temporary strength. Cash generation crisis despite reported profits: The most significant earnings characteristic is the severe disconnect between reported net income of 2.7 billion yen and operating cash flow of negative 3.5 billion yen, yielding a cash conversion ratio of negative 1.30 times. Trade receivables surged 179.8% to 19.3 billion yen, with days sales outstanding ballooning to approximately 177 days, more than double typical pharmaceutical industry norms. This working capital deterioration consumed all reported profits and then some, forcing reliance on financing cash flow of 3.8 billion yen to maintain liquidity. The negative free cash flow of 2.3 billion yen indicates the business is consuming rather than generating cash, a pattern that is unsustainable without fundamental improvement in collections or business model. Asset risk concentration requires monitoring: The balance sheet carries goodwill of 37.0 billion yen representing 53.7% of equity and total intangibles of 37.3 billion yen comprising 35.5% of assets, creating substantial impairment risk if business performance deteriorates. Combined with debt-to-EBITDA of 3.12 times, any asset writedowns could quickly pressure financial flexibility. The company's single-segment pharmaceutical R&D focus concentrates all performance risk in clinical development outcomes without diversification benefits. While cash reserves of 32.4 billion yen and equity ratio of 65.6% provide near-term stability, the structural issues of poor cash conversion, elevated receivables, and conservative forward guidance point to fundamental business model challenges that overshadow reported profit improvement.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.